Supernus Pharmaceuticals, Inc.
|$2.0 B||Market Cap|
|4.5%||EBIT / EV|
|5.3%||FCF / EV|
|327.5%||3yr Avg Revenue Growth|
Business Model Diligence
We do not yet have Business Model Diligence for this stock.
|Current member of one or more spells! Log in to see which ones.|
|The EBIT / Enterprise Value of 4.5% ranks as Below Average.|
|The Free Cash Flow / Enterprise Value of 5.3% ranks as Above Average.|
|The Return on Invested Capital Value of 107.3% ranks as Very High.|
|The Cash Return on Capital Value of 126.5% ranks as Very High.|
|The 3 Year Average Revenue Growth Value of 327.5% ranks as Very High.|
|Near-term Financial Health appears to be Very Good. The Current Ratio is 1.82.|
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi, which treats patients with epilepsy. It also develops product candidates for the treatment of impulsive aggression and for the treatment of attention deficit hyperactivity disorder. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.
|Exelixis, Inc. (EXEL)|
|Appian Corporation Class A (APPN)|
|AppFolio Inc Class A (APPF)|
|Hershey Company (HSY)|
|Harley-Davidson, Inc. (HOG)|